Compass Pathways is trading 11.4% up now at $13.14 after its Q2 update highlighted a steady clinical timeline and strong cash reserves.
- The company reaffirmed that the COMP360 NDA remains on track for completion in Q4 2026 as it shifts focus toward commercial execution.
- Investors are focusing on a robust cash position of $433.3 million, looking past a wider loss caused by a large non-cash warrant fair-value charge.
- Broader biotech sector strength and positive market sentiment are providing additional support for the stock's upward move.